Cargando…
Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study
We performed a prospective observational study of chronic myeloid leukemia (CML) patients after anti-SARS-CoV-2 BNT162b2 vaccination (VC). In total, 32 CML patients with tyrosine kinase inhibitor (TKI) therapy, 10 CML patients with treatment-free remission, and 16 healthy subjects participated in th...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501552/ https://www.ncbi.nlm.nih.gov/pubmed/36146482 http://dx.doi.org/10.3390/vaccines10091404 |
_version_ | 1784795503125331968 |
---|---|
author | Katagiri, Seiichiro Akahane, Daigo Otsuki, Shunsuke Suto, Arisa Yamada, Akiko Suguro, Tamiko Asano, Michiyo Yoshizawa, Seiichiro Tanaka, Yuko Furuya, Nahoko Fujimoto, Hiroaki Okabe, Seiichi Gotoh, Moritaka Ito, Yoshikazu Gotoh, Akihiko |
author_facet | Katagiri, Seiichiro Akahane, Daigo Otsuki, Shunsuke Suto, Arisa Yamada, Akiko Suguro, Tamiko Asano, Michiyo Yoshizawa, Seiichiro Tanaka, Yuko Furuya, Nahoko Fujimoto, Hiroaki Okabe, Seiichi Gotoh, Moritaka Ito, Yoshikazu Gotoh, Akihiko |
author_sort | Katagiri, Seiichiro |
collection | PubMed |
description | We performed a prospective observational study of chronic myeloid leukemia (CML) patients after anti-SARS-CoV-2 BNT162b2 vaccination (VC). In total, 32 CML patients with tyrosine kinase inhibitor (TKI) therapy, 10 CML patients with treatment-free remission, and 16 healthy subjects participated in the study. From April 2021 to September 2021, all cases (median age = 58 years) were vaccinated twice. Immunoglobulin G for SARS-CoV-2 spike protein (S-IgG) was measured at three timepoints (before the first VC, 1–5 weeks after the second VC (T1), and approximately 6 months after the second VC (T2)). S-IgG was not observed before the first VC in any participant. At T1, all cases had acquired S-IgG. There were no significant differences in S-IgG levels among groups. A paired sample comparison of median S-IgG titers between T1 and T2 in all groups showed a significant reduction in T2 S-IgG titers. There were no significant differences in S-IgG levels among groups. When all patients were analyzed, those aged ≥58 years had significantly lower S-IgG levels than those aged <58 years at T1. The BNT162b2 vaccine was highly effective in CML patients with or without TKIs, and S-IgG levels were as persistent as those in healthy individuals. |
format | Online Article Text |
id | pubmed-9501552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95015522022-09-24 Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study Katagiri, Seiichiro Akahane, Daigo Otsuki, Shunsuke Suto, Arisa Yamada, Akiko Suguro, Tamiko Asano, Michiyo Yoshizawa, Seiichiro Tanaka, Yuko Furuya, Nahoko Fujimoto, Hiroaki Okabe, Seiichi Gotoh, Moritaka Ito, Yoshikazu Gotoh, Akihiko Vaccines (Basel) Article We performed a prospective observational study of chronic myeloid leukemia (CML) patients after anti-SARS-CoV-2 BNT162b2 vaccination (VC). In total, 32 CML patients with tyrosine kinase inhibitor (TKI) therapy, 10 CML patients with treatment-free remission, and 16 healthy subjects participated in the study. From April 2021 to September 2021, all cases (median age = 58 years) were vaccinated twice. Immunoglobulin G for SARS-CoV-2 spike protein (S-IgG) was measured at three timepoints (before the first VC, 1–5 weeks after the second VC (T1), and approximately 6 months after the second VC (T2)). S-IgG was not observed before the first VC in any participant. At T1, all cases had acquired S-IgG. There were no significant differences in S-IgG levels among groups. A paired sample comparison of median S-IgG titers between T1 and T2 in all groups showed a significant reduction in T2 S-IgG titers. There were no significant differences in S-IgG levels among groups. When all patients were analyzed, those aged ≥58 years had significantly lower S-IgG levels than those aged <58 years at T1. The BNT162b2 vaccine was highly effective in CML patients with or without TKIs, and S-IgG levels were as persistent as those in healthy individuals. MDPI 2022-08-27 /pmc/articles/PMC9501552/ /pubmed/36146482 http://dx.doi.org/10.3390/vaccines10091404 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Katagiri, Seiichiro Akahane, Daigo Otsuki, Shunsuke Suto, Arisa Yamada, Akiko Suguro, Tamiko Asano, Michiyo Yoshizawa, Seiichiro Tanaka, Yuko Furuya, Nahoko Fujimoto, Hiroaki Okabe, Seiichi Gotoh, Moritaka Ito, Yoshikazu Gotoh, Akihiko Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study |
title | Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study |
title_full | Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study |
title_fullStr | Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study |
title_full_unstemmed | Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study |
title_short | Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study |
title_sort | tyrosine kinase inhibitors do not promote a decrease in sars-cov-2 anti-spike igg after bnt162b2 vaccination in chronic myeloid leukemia: a prospective observational study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501552/ https://www.ncbi.nlm.nih.gov/pubmed/36146482 http://dx.doi.org/10.3390/vaccines10091404 |
work_keys_str_mv | AT katagiriseiichiro tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy AT akahanedaigo tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy AT otsukishunsuke tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy AT sutoarisa tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy AT yamadaakiko tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy AT sugurotamiko tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy AT asanomichiyo tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy AT yoshizawaseiichiro tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy AT tanakayuko tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy AT furuyanahoko tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy AT fujimotohiroaki tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy AT okabeseiichi tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy AT gotohmoritaka tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy AT itoyoshikazu tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy AT gotohakihiko tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy |